Akers Biosciences Inc. (AKER): Price and Financial Metrics


Akers Biosciences Inc. (AKER): $2.47

-0.26 (-9.52%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AKER to Watchlist
Sign Up

Industry: Biotech


Ranked

of 493

in industry

AKER Stock Summary

  • With a year-over-year growth in debt of -85.02%, Akers Biosciences Inc's debt growth rate surpasses only 2.64% of about US stocks.
  • Revenue growth over the past 12 months for Akers Biosciences Inc comes in at -75.17%, a number that bests only 2.11% of the US stocks we're tracking.
  • Akers Biosciences Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -71.69%, greater than the shareholder yield of just 3.31% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Akers Biosciences Inc are MNDO, SINT, APVO, ADXS, and TSEM.
  • AKER's SEC filings can be seen here. And to visit Akers Biosciences Inc's official web site, go to www.akersbio.com.

AKER Stock Price Chart Interactive Chart >

Price chart for AKER

AKER Price/Volume Stats

Current price $2.47 52-week high $6.97
Prev. close $2.73 52-week low $1.65
Day low $2.40 Volume 1,583,500
Day high $3.04 Avg. volume 769,876
50-day MA $3.32 Dividend yield N/A
200-day MA $3.03 Market Cap 41.13M

Akers Biosciences Inc. (AKER) Company Bio


Akers Biosciences, Inc. focuses on the development of a vaccine candidate against SARS-CoV-2, a coronavirus causing a pandemic. It has a collaboration agreement with Premas Biotech PVT Ltd. The company was founded in 1989 and is headquartered in Thorofare, New Jersey.


AKER Latest News Stream


Event/Time News Detail
Loading, please wait...

AKER Latest Social Stream


Loading social stream, please wait...

View Full AKER Social Stream

Latest AKER News From Around the Web

Below are the latest news stories about Akers Biosciences Inc that investors may wish to consider to help them evaluate AKER as an investment opportunity.

Akers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of Merger

Akers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of Merger

Yahoo | April 16, 2021

Akers’ Proposed Merger Partner MyMD Pharmaceuticals Announces Plans to Initiate COVID-19 Inflammatory Depression Trial

Akers Biosciences, Inc. (NASDAQ: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. ("MyMD"), a clinical stage pharmaceutical company committed to extending health lifespan and treating immune mediated illnesses, has reached an agreement with a major medical school to conduct a Phase 2 clinical trial to investigate the effectiveness of MYMD-1 to treat immune mediated depression in patients affected with COVID-19. MYMD believes that this investigator-initiated study is the first of its kind and addresses a significant unmet medical need.

Yahoo | April 13, 2021

Akers’ Proposed Merger Partner MyMD Pharmaceuticals Announces Formation of Scientific Advisory Board

Akers Biosciences, Inc. (Nasdaq: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. ("MyMD"), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, has completed the formation of its Scientific Advisory Board (SAB). The board will be chaired by Katharine Whartenby, Ph.D., associate professor at the Johns Hopkins University School of Medicine Department of Neurology, Department of Oncology and in Cellular and Molecular Medicine.

Yahoo | April 12, 2021

We Think Akers Biosciences (NASDAQ:AKER) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | March 21, 2021

SHAREHOLDER ALERT: WeissLaw LLP Reminds TLRY, CBLI, AKER and OBLN Shareholders About Its Ongoing Investigations

Tilray, Inc. (NASDAQ: TLRY)

Yahoo | March 19, 2021

Read More 'AKER' Stories Here

AKER Price Returns

1-mo N/A
3-mo N/A
6-mo -55.58%
1-year -75.00%
3-year -98.05%
5-year -99.78%
YTD -37.94%
2020 -37.81%
2019 -88.20%
2018 8.65%
2017 -93.16%
2016 57.02%

Continue Researching AKER

Want to see what other sources are saying about Akers Biosciences Inc's financials and stock price? Try the links below:

Akers Biosciences Inc (AKER) Stock Price | Nasdaq
Akers Biosciences Inc (AKER) Stock Quote, History and News - Yahoo Finance
Akers Biosciences Inc (AKER) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8371 seconds.